Esperion Therapeutics (NASDAQ:ESPR) Rating Reiterated by HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a report on Tuesday. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.33.

Esperion Therapeutics Trading Down 5.5 %

Esperion Therapeutics stock traded down $0.13 during mid-day trading on Wednesday, hitting $2.24. The stock had a trading volume of 2,779,667 shares, compared to its average volume of 6,914,648. The firm’s 50 day moving average is $2.32 and its 200 day moving average is $2.07. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The firm has a market capitalization of $424.26 million, a P/E ratio of -1.06 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same quarter in the previous year, the company earned ($0.76) earnings per share. As a group, equities research analysts forecast that Esperion Therapeutics will post -0.68 earnings per share for the current year.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ESPR. Spire Wealth Management raised its stake in shares of Esperion Therapeutics by 69.2% in the fourth quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 7,267 shares during the period. Private Portfolio Partners LLC bought a new stake in Esperion Therapeutics in the fourth quarter worth about $30,000. Herbst Group LLC purchased a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $28,000. Summit Financial LLC grew its stake in shares of Esperion Therapeutics by 66.8% during the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 10,355 shares during the last quarter. Finally, PSI Advisors LLC raised its holdings in shares of Esperion Therapeutics by 161.5% in the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 10,500 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.